吴婷 - 厦门大学 - 公共卫生学院

个人简介

吴婷，教授，博士生导师，1994年毕业于上海医科大学；2000年毕业于复旦大学药学院(原上海医科大学药学院)，获博士学位。2003年1月起进入厦门大学。

研究领域

主要研究方向为疫苗临床试验和传染病的流行病学研究，目前做为国家传染病诊断试剂与疫苗工程技术研究中心“临床试验与流行病学研究”方向的组长开展传染病防控及流行病学相关研究，包括人乳头瘤病毒（HPV）16/18型双价疫苗和HPV6/11双价疫苗的I-III期临床研究及相关流行病学研究；戊型肝炎病毒相关流行病学研究；巨细胞病毒母婴传播风险研究。

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

[1] Wei FX, Guo M, Huang SJ, Li MQ, Cui XL, Su YY, Wu X, Ma XJ, Zheng Y, Huang Y, Wang L, Pan LL, Wu T*, Zhang J*, Xia NS. Sex differences in the incidence and clearance of anogenital human papillomavirus infection in Liuzhou, China: an observational cohort study. Clin Infect Dis, 2019, accepted (共通讯作者) (IF: 9.117) [2] Wei FX, Li MQ, Wu X, Yin K, Lan J, Sheng W, Guo M, Huang SJ, Wang Y, Li YP, Li RC, Su YY, Wu T*, Zhang J, and Xia NS. The Prevalence and Concordance of Human Papillomavirus Infection in Different Anogenital Sites among Men and Women in Liuzhou, China: a Population-Based Study. Int J Cancer, 2018, 142(6)：1244-1251 (IF: 7.360) [3] Wei FX, Sheng W, Wu X, Yin K, Lan J, Huang Y, Ma XJ, Zheng Y, Zhuang SJ, Huang SJ, Su YY, Li MQ*, Wu T*, Zhang J, and Xia NS. Incidence of genital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system. Emerging Microbes & Infections, 2017, 6, e113 (共通讯作者) (IF: 6.032) [4] Su YY, Huang SJ, Guo M, Zhao J, Yu H, He WG, Jiang HM, Wang YJ, Zhang XF, Cai JP, Yang CL, Wang ZZ, Zhu FC, Wu T*, Zhang J*, Xia NS. Persistence of antibodies acquired by natural hepatitis E virus infection and the effects of booster vaccination. Clin Microbiol Infect, 2017, 23(5): 336.e1-336.e4 (共通讯作者) (IF: 5.3) [5] Wei FX, Yin K, Wu X, Lan J, Huang SJ, Sheng W, Zhao J, Su YY, Wang Y, Li YP, Li RC, Zhang J, Li MQ*, Wu T*, and Xia NS. Human papillomavirus (HPV) prevalence and associated factors in women and men in south China: a population-based study.Emerging Microbes & Infections, 2016, 5(11): e119 (共通讯作者) （IF:6.032） [6] Chen S, Zhou Z, Wei FX, Huang SJ, Tan Z, Fang Y, Zhu FC, Wu T*, Zhang J*, Xia NS. Modeling the long-term antibody response of a hepatitis E vaccine. Vaccine, 2015, 33: 4124-4129.（IF:3.624） [7] Wu T#, Hu YM#*, Li J#, Chu K, Huang SJ, Zhao H, Wang ZZ, Yang CL, Jiang HM, Wang YJ, Lin ZJ, Pan HR, Sheng W, Wei FX, Li SW, Wang Y, Zhu FC, Li CG, Zhang J*, Xia NS. Immunogenicity and safety of an E. coli–produced bivalent human papillomavirus (type 16 and 18) vaccine: a randomized controlled phase 2 clinical trial. Vaccine, 2015, 33: 3940–3946.（IF:3.624） [8] Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J*, Xia NS*. Safety of hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology, 2012, 55(6): 2038.（IF:11.665）. [9] Zhang J*, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q, Guo M, Liu XH, Li JX, Yang CL, Tang Q, Jiang RJ, Pan HR, Li YM, Shih JW, Ng MH, Zhu FC*, Xia NS*. Long-Term Efficacy of a Hepatitis E Vaccine. New Engl J Med, 2015, 372(10): 914-922. (IF 54.42) [10]Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW, Xia NS*. Efficacy and Safety of a Recombinant Hepatitis E Vaccine in Healthy Adults: A Large-scale, Double-blind, Randomized, Placebo Controlled Phase III Clinical Trial. Lancet, 2010, 376: 895–902. （IF:33.633）